Business Wire - October 5, 2005
Highlights of some of Samaritan's Early Stage Unique Out-licensing Opportunities
-- An Alzheimer's drug to stop, and reverse, memory loss.
-- An oral chemotherapy-acting drug to kill Cancerous tumors, and maintain healthy cells, at the same time.
-- A Cancer diagnostic that identifies one Cancer cell out of a million, which has the potential to be used for early preventive treatment.
Dr. Janet Greeson, CEO of Samaritan stated, "Dr. Christos Dakas has an extremely successful track record in marketing, specialized and niche pharmaceuticals, in Greece, and Eastern Europe. With his former Company, he dramatically increased sales for these markets inspiring us to jump to the other side of the table, at this premier European partnering venue. We are looking to in-license niche pharmaceuticals, the major pharmaceuticals customarily license out in these regions. In-licensing other drugs for marketing would not only complement the sales force we intend to build for our proprietary HIV entry inhibitor drug upon approval, it would also give us a source of revenue."
Samaritan Pharmaceuticals Europe established its European headquarters in Athens, Greece, to allow access to the markets of Eastern Europe, Asia and Africa. Samaritan Europe is swiftly implementing an infrastructure to market, upon regulatory approval, its HIV oral entry inhibitor drug in Greece and Eastern Europe.
Samaritan Pharmaceuticals: "We LIV....to Save Lives."
Samaritan Pharmaceuticals is a drug development company driven to commercialize innovative drugs. Samaritan, in collaboration with Georgetown University, is advancing 8 promising compounds, out of its pipeline of 250 possible drug candidates; all of which have the potential to create revenue-generating opportunities. Additional information is at www.samaritanpharma.com.
Disclaimer
The company disclaims any information that is created by an outside party and endorses only information that is communicated by its press releases, filings and Web site. This news release contains forward-looking statements that reflect management's current beliefs about the potential for its drug candidates, science and technology. However, as with any biopharmaceutical under development, there are significant risks and uncertainties in the process of development and regulatory review. There are no guarantees that products will prove to be commercially successful. For additional information about the factors that affect the company's business, please read the company's latest Form 10-K filed April 15, 2005. The company undertakes no duty to update forward-looking statements.
CONTACT: Samaritan Pharmaceuticals, Inc.
Gene Boyle, 702-735-7001 -- GeneBoyle@SamaritanPharma.com
or
Samaritan Pharmaceuticals Europe, Athens
Dr. Christos Dakas, 30 210 4196668 -- Cdakas@SamaritanPharma.com
SOURCE: Samaritan Pharmaceuticals
051005
BW051004
Copyright © 2005 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .